Aptose Biosciences to Go Private in C$2.41 Per Share Arrangement

summarizeSummary

This SC 13E3 filing confirms a definitive agreement for Aptose Biosciences Inc. to be acquired and taken private by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., for C$2.41 per common share. The transaction, valued at approximately $3.5 million, represents a significant premium to the current stock price and will result in the company's common shares being delisted from public exchanges. While existing shareholders will receive cash consideration at a premium, the event marks the end of Aptose Biosciences as a publicly traded entity, fundamentally altering its investment profile and removing it from the public market.

check_boxKey Events

• Going Private Transaction Announced

  Aptose Biosciences Inc. will be acquired by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., through a Plan of Arrangement.

• Shareholders to Receive C$2.41 Per Share

  Public shareholders will receive C$2.41 in cash for each common share, which translates to approximately $1.71 USD, representing a premium over the current trading price.

• Delisting and Deregistration

  Upon completion, Aptose Biosciences Inc. will become a wholly-owned subsidiary, cease to be a reporting issuer, and its shares will be delisted from the Toronto Stock Exchange and OTC Markets.

• Board Recommends Approval

  The company's Board of Directors, based on the recommendation of an independent special committee and a fairness opinion, unanimously approved and recommended the Arrangement to shareholders.

auto_awesomeAnalysis

This SC 13E3 filing confirms a definitive agreement for Aptose Biosciences Inc. to be acquired and taken private by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., for C$2.41 per common share. The transaction, valued at approximately $3.5 million, represents a significant premium to the current stock price and will result in the company's common shares being delisted from public exchanges. While existing shareholders will receive cash consideration at a premium, the event marks the end of Aptose Biosciences as a publicly traded entity, fundamentally altering its investment profile and removing it from the public market.